| Name | Title | Contact Details |
|---|
Northern Lights Health Region is a Fort Mcmurray, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bio Reference Laboratories Inc is a Elmwood Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Miraca Life Sciences serves more than 5,500 patients each day, providing expert pathology services in the fields of dermatopathology, breast pathology, gastroenterology, hematology/oncology and urology. Additionally, Miraca has provided health IT consulting services to hundreds of practices, helping providers with programs such as MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012. Miraca Life Sciences is a subsidiary of Miraca Holdings Inc., one of Japan`s largest clinical diagnostics and laboratory testing service providers. As a leader in anatomic pathology, Miraca Life Sciences combines the rigor of an academic medical institution with the innovative spirit of a technology company. By working for Miraca, you will have the opportunity to contribute alongside top multidisciplinary talented professionals, who are dedicated to meeting the needs of our clients and their patients. You will work in a state-of-the-art environment with cutting-edge tools, breakthrough technologies and with world-renowned thought leaders. The company offers a forward-thinking business model seeking to make a profound difference in the quality of care for patients.
Alberta Cancer Board is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.